8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2007 (August 20, 2007)

Commission File Number: 0-24260

Amedisys, Inc.

(Exact Name of Registrant as specified in Charter)

Delaware	11-3131700
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Information to be included in the report

Section 7 — Regulation FD

Item 7.01. Regulation FD Disclosure.

On August 20, 2007, Amedisys, Inc. (the “Company”) issued a press release announcing that it had filed a shelf Registration Statement on Form S-3. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of this Current Report on Form 8-K, the information presented herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1933, as amended, except as previously set forth by specific reference in such a filing.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not applicable

(b) Pro Forma Financial Information.

Not applicable

(c) Shell Company Transactions.

Not applicable

(d) Exhibits

99.1 Press release dated August 20, 2007, announcing the Company’s filing of a shelf Registration Statement on Form S-3.

2

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Amedisys, Inc.
Date: August 21, 2007	By:	/s/ Dale E. Redman
		Dale E. Redman Chief Financial Officer

3

Exhibit Index

Exhibit No.	Description
EX-99.1	Press release dated August 20, 2007, announcing the Company’s filing of a shelf Registration Statement on Form S-3.

4

EX-99.1

Exhibit 99.1

Contact:	Amedisys, Inc.	Amedisys, Inc.
	Senior Vice President - Finance	Chief Financial Officer
	Thomas J. Dolan	Dale E. Redman
	225.292.2031	225.292.2031
	tdolan@amedisys.com	dredman@amedisys.com

AMEDISYS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT

BATON ROUGE, Louisiana (August 20, 2007) – Amedisys, Inc. (NASDAQ: “AMED”, Amedisys or the “Company”), one of America’s leading home health nursing companies, announced today that it filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission “SEC” which, when declared effective, will permit the Company to offer and sell, from time to time, in one or more offerings, shares of its common stock or preferred stock or any combination of such securities, for proceeds in an aggregate amount up to $250 million. The terms of any such future offering will be established at the time of the offering. Proceeds from the sale of any securities will be used for the purposes described in the prospectus or a prospectus supplement filed at the time of an offering. Amedisys has no immediate plans to offer or sell any securities under the registration statement.

“With minimal debt outstanding, and a cash balance at June 30, 2007 of over $97 million, Amedisys has no immediate plans to offer or sell any securities under this registration statement”, said Bill Borne, the Chief Executive Officer of Amedisys, Inc. “However, we believe having a shelf registration in place will provide us with additional flexibility in accessing capital markets in the future”.

The shelf registration statement relating to these securities has not yet become effective. The securities offered by the Company under the registration statement may not be sold, nor may offers to buy the securities be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s services in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Additional information on the Company can be found at:

www.amedisys.com